Abstract
The gap between real‐world and guidelines in the use of sodium–glucose cotransporter 2 inhibitors for heart failure patients with reduced ejection fraction: Is it underestimated or overestimated? Letter regarding the article ‘Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry’
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
